Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 22-Mar-24 4:55 PM View:  | Shah Sujal Chief Executive Officer Director | Cymabay Therapeutics, Inc. (CBAY) | 22-Mar-24 | Disposition | 406,670 | -- | -- | (100%) 406.67K to 0 | |
| 22-Mar-24 5:03 PM View: | Shantharam Harish Chief Financial Officer | Cymabay Therapeutics, Inc. (CBAY) | 22-Mar-24 | Disposition | 20,125 | -- | -- | (100%) 20.13K to 0 | |
| 22-Mar-24 4:55 PM View: | Wills Robert James Director | Cymabay Therapeutics, Inc. (CBAY) | 22-Mar-24 | Disposition | 30,000 | -- | -- | (100%) 30.0K to 0 | |
| 22-Mar-24 5:06 PM View: | McWherter Charles President of R&D | Cymabay Therapeutics, Inc. (CBAY) | 22-Mar-24 | Disposition | 46,938 | -- | -- | (100%) 46.94K to 0 | |
| 22-Mar-24 5:02 PM View: | Dickinson Klara Chief Regulatory Officer | Cymabay Therapeutics, Inc. (CBAY) | 22-Mar-24 | Disposition | 21,000 | -- | -- | (100%) 21.0K to 0 | |
| 22-Mar-24 4:59 PM View: | Quinlan Paul T General Counsel | Cymabay Therapeutics, Inc. (CBAY) | 22-Mar-24 | Disposition | 70,262 | -- | -- | (100%) 70.26K to 0 | |
| 22-Mar-24 4:51 PM View: | Emster Kurt von Director | Cymabay Therapeutics, Inc. (CBAY) | 22-Mar-24 | Disposition | 90,000 | -- | -- | (100%) 90.0K to 0 | |
| 15-Mar-24 4:02 PM View: | Quinlan Paul T General Counsel | Cymabay Therapeutics, Inc. (CBAY) | 13-Mar-24 | Option Exercise | 41,824 | $7.89 | $329,991.00 | 147% 28.44K to 70.26K | |
| 15-Mar-24 4:03 PM View: | Shah Sujal Chief Executive Officer Director | Cymabay Therapeutics, Inc. (CBAY) | 13-Mar-24 | Option Exercise | 139,119 | $4.72 | $655,959.00 | 52% 267.55K to 406.67K | |
| 14-Feb-24 6:43 PM View: | Dorling Janet Director | Cymabay Therapeutics, Inc. (CBAY) | 12-Feb-24 | Option Exercise | 6,000 | $4.63 | $27,780.00 | 100% 0 to 6.0K | |
| 14-Feb-24 6:43 PM View: | Dorling Janet Director | Cymabay Therapeutics, Inc. (CBAY) | 12-Feb-24 | Planned Option Sale | 6,000 | $31.97 | $191,849.00 | (100%) 6.0K to 0 | |
| 26-Jan-24 6:33 PM View: | Shantharam Harish Chief Financial Officer | Cymabay Therapeutics, Inc. (CBAY) | 24-Jan-24 | Grant | 20,125 | -- | -- | 100% 0 to 20.13K | |
| 26-Jan-24 6:29 PM View: | McWherter Charles President of R&D | Cymabay Therapeutics, Inc. (CBAY) | 24-Jan-24 | Grant | 31,938 | -- | -- | 213% 15.0K to 46.94K | |
| 26-Jan-24 6:30 PM View: | Dickinson Klara Chief Regulatory Officer | Cymabay Therapeutics, Inc. (CBAY) | 24-Jan-24 | Grant | 21,000 | -- | -- | 100% 0 to 21.0K | |
| 26-Jan-24 6:28 PM View: | Quinlan Paul T General Counsel | Cymabay Therapeutics, Inc. (CBAY) | 24-Jan-24 | Grant | 28,438 | -- | -- | 100% 0 to 28.44K | |
| 26-Jan-24 6:27 PM View: | Shah Sujal Chief Executive Officer Director | Cymabay Therapeutics, Inc. (CBAY) | 24-Jan-24 | Grant | 96,250 | -- | -- | 56% 171.3K to 267.55K | |
| 22-Jan-24 6:59 PM View: | McWherter Charles President of R&D | Cymabay Therapeutics, Inc. (CBAY) | 19-Jan-24 | Option Exercise | 18,403 | $7.09 | $130,522.00 | 123% 15.0K to 33.4K | |
| 22-Jan-24 6:59 PM View: | McWherter Charles President of R&D | Cymabay Therapeutics, Inc. (CBAY) | 19-Jan-24 | Planned Option Sale | 18,403 | $23.67 | $435,645.00 | (55%) 33.4K to 15.0K | |
| 16-Jan-24 7:07 PM View: | Quinlan Paul T General Counsel | Cymabay Therapeutics, Inc. (CBAY) | 16-Jan-24 | Planned Option Sale | 5,000 | $23.58 | $117,898.00 | (100%) 5.0K to 0 | |
| 16-Jan-24 7:07 PM View: | Quinlan Paul T General Counsel | Cymabay Therapeutics, Inc. (CBAY) | 16-Jan-24 | Option Exercise | 5,000 | $2.94 | $14,700.00 | 100% 0 to 5.0K | |
| 16-Jan-24 7:07 PM View: | Menold Daniel Vice President, Finance | Cymabay Therapeutics, Inc. (CBAY) | 16-Jan-24 | Option Exercise | 10,000 | $4.05 | $40,500.00 | 100% 0 to 10.0K | |
| 16-Jan-24 7:07 PM View: | Menold Daniel Vice President, Finance | Cymabay Therapeutics, Inc. (CBAY) | 16-Jan-24 | Planned Option Sale | 10,000 | $23.58 | $235,806.00 | (100%) 10.0K to 0 | |
| 10-Jan-24 8:35 PM View: | Dorling Janet Director | Cymabay Therapeutics, Inc. (CBAY) | 10-Jan-24 | Option Exercise | 6,000 | $4.63 | $27,780.00 | 100% 0 to 6.0K | |
| 10-Jan-24 8:35 PM View: | Dorling Janet Director | Cymabay Therapeutics, Inc. (CBAY) | 10-Jan-24 | Planned Option Sale | 6,000 | $23.86 | $143,144.00 | (100%) 6.0K to 0 | |
| 18-Dec-23 8:04 PM View: | McWherter Charles President of R&D | Cymabay Therapeutics, Inc. (CBAY) | 18-Dec-23 | Option Exercise | 11,332 | $5.00 | $56,660.00 | 76% 15.0K to 26.33K | |
| 18-Dec-23 8:04 PM View: | McWherter Charles President of R&D | Cymabay Therapeutics, Inc. (CBAY) | 18-Dec-23 | Planned Option Sale | 11,332 | $21.48 | $243,441.00 | (43%) 26.33K to 15.0K | |
| 15-Dec-23 4:35 PM View: | Quinlan Paul T General Counsel | Cymabay Therapeutics, Inc. (CBAY) | 15-Dec-23 | Option Exercise | 5,000 | $2.94 | $14,700.00 | 100% 0 to 5.0K | |
| 15-Dec-23 4:38 PM View: | Menold Daniel Vice President, Finance | Cymabay Therapeutics, Inc. (CBAY) | 15-Dec-23 | Option Exercise | 21,497 | $6.39 | $137,420.00 | 100% 0 to 21.5K | |
| 15-Dec-23 4:38 PM View: | Menold Daniel Vice President, Finance | Cymabay Therapeutics, Inc. (CBAY) | 15-Dec-23 | Planned Option Sale | 21,497 | $21.99 | $472,646.00 | (100%) 21.5K to 0 | |
| 15-Dec-23 4:35 PM View: | Quinlan Paul T General Counsel | Cymabay Therapeutics, Inc. (CBAY) | 15-Dec-23 | Planned Option Sale | 5,000 | $21.98 | $109,902.00 | (100%) 5.0K to 0 | |
| 11-Dec-23 7:03 PM View: | Shah Sujal Chief Executive Officer Director | Cymabay Therapeutics, Inc. (CBAY) | 11-Dec-23 | Planned Option Sale | 64,865 | $20.00 | $1,297,170.00 | (27%) 236.17K to 171.3K | |
| 11-Dec-23 7:03 PM View: | Shah Sujal Chief Executive Officer Director | Cymabay Therapeutics, Inc. (CBAY) | 11-Dec-23 | Option Exercise | 64,865 | $5.00 | $324,325.00 | 38% 171.3K to 236.17K | |
| 11-Dec-23 7:01 PM View: | Dorling Janet Director | Cymabay Therapeutics, Inc. (CBAY) | 11-Dec-23 | Option Exercise | 6,000 | $4.63 | $27,780.00 | 100% 0 to 6.0K | |
| 11-Dec-23 7:01 PM View: | Dorling Janet Director | Cymabay Therapeutics, Inc. (CBAY) | 11-Dec-23 | Planned Option Sale | 6,000 | $20.07 | $120,422.00 | (100%) 6.0K to 0 | |
| 17-Nov-23 5:58 PM View: | McWherter Charles President of R&D | Cymabay Therapeutics, Inc. (CBAY) | 17-Nov-23 | Option Exercise | 11,342 | $5.00 | $56,710.00 | 76% 15.0K to 26.34K | |
| 17-Nov-23 5:58 PM View: | McWherter Charles President of R&D | Cymabay Therapeutics, Inc. (CBAY) | 17-Nov-23 | Planned Option Sale | 11,342 | $18.28 | $207,293.00 | (43%) 26.34K to 15.0K | |
| 17-Nov-23 5:57 PM View: | Quinlan Paul T General Counsel | Cymabay Therapeutics, Inc. (CBAY) | 15-Nov-23 | Option Exercise | 5,000 | $2.94 | $14,700.00 | 100% 0 to 5.0K | |
| 17-Nov-23 5:57 PM View: | Menold Daniel Vice President, Finance | Cymabay Therapeutics, Inc. (CBAY) | 15-Nov-23 | Planned Option Sale | -- | $17.38 | -- | 0% -- | |
| 17-Nov-23 5:57 PM View: | Quinlan Paul T General Counsel | Cymabay Therapeutics, Inc. (CBAY) | 15-Nov-23 | Planned Option Sale | 5,000 | $17.38 | $86,889.00 | (100%) 5.0K to 0 | |
| 14-Nov-23 10:00 PM View: | Shah Sujal Chief Executive Officer Director | Cymabay Therapeutics, Inc. (CBAY) | 13-Nov-23 | Planned Option Sale | 64,863 | $15.89 | $1,030,660.00 | (27%) 236.16K to 171.3K | |
| 14-Nov-23 10:00 PM View: | Shah Sujal Chief Executive Officer Director | Cymabay Therapeutics, Inc. (CBAY) | 13-Nov-23 | Option Exercise | 64,863 | $5.00 | $324,315.00 | 38% 171.3K to 236.16K | |
| 14-Nov-23 10:00 PM View: | Dorling Janet Director | Cymabay Therapeutics, Inc. (CBAY) | 10-Nov-23 | Option Exercise | 7,000 | $4.63 | $32,410.00 | 100% 0 to 7.0K | |
| 14-Nov-23 10:00 PM View: | Dorling Janet Director | Cymabay Therapeutics, Inc. (CBAY) | 10-Nov-23 | Planned Option Sale | 7,000 | $15.24 | $106,700.00 | (100%) 7.0K to 0 | |
| 18-Oct-23 6:22 PM View: | McWherter Charles President of R&D | Cymabay Therapeutics, Inc. (CBAY) | 18-Oct-23 | Planned Option Sale | 21,743 | $14.07 | $305,941.00 | (59%) 36.74K to 15.0K | |
| 18-Oct-23 6:22 PM View: | McWherter Charles President of R&D | Cymabay Therapeutics, Inc. (CBAY) | 18-Oct-23 | Option Exercise | 21,743 | $5.00 | $108,715.00 | 145% 15.0K to 36.74K | |
| 18-Oct-23 6:21 PM View: | Quinlan Paul T General Counsel | Cymabay Therapeutics, Inc. (CBAY) | 16-Oct-23 | Option Exercise | 5,000 | $2.94 | $14,700.00 | 100% 0 to 5.0K | |
| 18-Oct-23 6:21 PM View: | Quinlan Paul T General Counsel | Cymabay Therapeutics, Inc. (CBAY) | 16-Oct-23 | Planned Option Sale | 5,000 | $13.76 | $68,798.00 | (100%) 5.0K to 0 | |
| 18-Oct-23 6:22 PM View: | Menold Daniel Vice President, Finance | Cymabay Therapeutics, Inc. (CBAY) | 16-Oct-23 | Planned Option Sale | -- | $13.76 | -- | 0% -- | |
| 10-Oct-23 5:04 PM View: | Shah Sujal Chief Executive Officer Director | Cymabay Therapeutics, Inc. (CBAY) | 09-Oct-23 | Option Exercise | 64,861 | $5.00 | $324,305.00 | 38% 171.3K to 236.16K | |
| 10-Oct-23 5:04 PM View: | Shah Sujal Chief Executive Officer Director | Cymabay Therapeutics, Inc. (CBAY) | 09-Oct-23 | Planned Option Sale | 64,861 | $14.20 | $921,286.00 | (27%) 236.16K to 171.3K |
